ROCHESTER, N.Y.—Bausch + Lomb, the global eye health company, has
named Robert E. Grant chief executive officer and president of its
global surgical business, effective Aug. 1.
“Robert is an exceptional leader and innovator in the medical
products industry, with global operating expertise extending across
devices and pharmaceuticals,” said Brent Saunders, CEO, Bausch + Lomb.
“His recruitment is another successful step in the actions we are
implementing to transform Bausch + Lomb into a high-performance global
competitor,” adding, “He brings a track record of rapid value creation,
powerful leadership and a relentless focus on the customer that can take
our surgical business to a new level of performance—while also helping
us to build strength and execution excellence across the company.”
“I am very excited to join Bausch + Lomb. I am confident that the
company will create tremendous value, push product development to new
heights, and play a leading role in the future of the global ophthalmic
industry,” commented Grant. “With a state-of-the-art product portfolio
and a keen focus on the customer, we will lead innovation and growth in
this dynamic market segment.”
In 2006, Grant began his tenure as Allergan’s corporate vice
president and president, Allergan Medical, where he led the $3.4 billion
Allergan-Inamed post-acquisition integration. His leadership at
Allergan Medical included the development of the multibillion dollar
medical rejuvenation industry through a portfolio of products such as
BOTOX Cosmetic, JUVEDERM injectable gel and the LAP-BAND Adjustable
Gastric Banding System.
J. Andy Corley, the president of Bausch + Lomb’s Surgical
business since 2008, will transition into a role as senior advisor to
Brent Saunders and the B+L senior leadership team. “Andy has played a
decisive role in building and positioning our Surgical business for
future success, and he has also made very important contributions to the
evolution of B+L as a whole,” said Saunders. “We thank him for what he
has achieved. We will value Andy’s continued advice and counsel as we
continue the positive transformation of our company.”
■
■